5. Compound according to any preceeding claim, selected from the following list:

I(a): 2-[3-[[2-fluoro-5-(3-fluorophenyl)phenyl]methylamino]phenoxy]acetic acid
I(b): 2-[2,4-difluoro-3-[[2-fluoro-5-(3-fluorophenyl)phenyl]methylamino]phenoxy] acetic acid
I(c): 2-[2,4-difluoro-3-[[5-(3-fluorophenyl)-2-methyl-phenyl]methylamino]phenoxy] acetic acid
I(d): 2-[2,4-difluoro-3-[[3-(3-fluorophenyl)-5-methyl-phenyl]methylamino]phenoxy] acetic acid
I(e): 2-[2,4-difluoro-3-[[3-(3-fluorophenyl)phenyl]methylamino]phenoxy]acetic acid
I(f): 2-[2,4-difluoro-3-[[2-fluoro-3-(3-fluorophenyl)-5-hydroxy-phenyl]methylamino] phenoxy] acetic acid
I(g): 2-[2,4-difluoro-3-[[2-fluoro-3-(3-fluorophenyl)-5-methylphenyl] methylamino] phenoxy] acetic acid,
or one of its enantiomers.

6. Compound according to any preceeding claim, where the compound is 2-[2,4-difluoro-3-[[2-fluoro-5-(3-fluorophenyl)phenyl]methylamino]phenoxy] acetic acid.

7. Compound of formula (I) or one of its prodrugs according to any preceding claim, ~~characterized in that~~wherein the prodrug of the drug of formula (I) is a compound of formula (II):



II

R1a represents H, an halogen, a (C1-C6)alkyl or a CN;

II(a): ethyl 2-[2,4-difluoro-3-[[2-fluoro-5-(3-fluorophenyl)phenyl]methylamino] phenoxy] acetate
II(c): methyl 2-[2,4-difluoro-3-[[2-fluoro-5-(3-fluorophenyl)phenyl]methylamino] phenoxy] acetate
II(d): isopropyl 2-[2,4-difluoro-3-[[2-fluoro-5-(3-fluorophenyl) phenyl] methylamino] phenoxy]acetate,
or one of its enantiomers

11. Compound according to any one of claims 7 to 10, where the compound is isopropyl 2-[2,4-difluoro-3-[[2-fluoro-5-(3-fluorophenyl)phenyl]methylamino] phenoxy]acetate.

12. Process for preparing a compound of formula (I) or one of its prodrugs according to any one of claims 1 to 11, ~~characterized in that~~wherein a compound of formula (XI):



XI

is reduced to give a compound of formula (IX),:



IX

which is reacted with BrCH2COR6 to give a compound of formula (II),
in which R1a, R1b, R1c, R2, R3, R4, R5, R7, R8 and R6 are as defined in claims 1 to 11.

13. Compound of formula (III):



III

in which R2, R3, R4, R5, R7 and R8 are as defined in claims 1 to 11, or one of its enantiomers.

14. Compound of formula (IV):



IV

in which R1a, R1b, R1c and R6 are as defined in claims 1 to 11, or one of its enantiomers.

15. Compound of formula (VI):



VI

in which R1a, R1b and R1c are as defined in claims 1 to 11, or one of its enantiomers.

16. Compound of formula (X):



X ,

in which R1a, R1b and R1c are as defined in claims 1 to 11, or one of its enantiomers.

17. Medicament, characterized in that it comprises a compound of formula (I) or one of its prodrugs according to any one of claims 1 to 11.

18. Medicament according to claim 17 characterized in that the prodrug is a compound of formula (II) as defined in claims 7 to 11.

19. Pharmaceutical composition, characterized in that it comprises a compound of formula (I) or one of its prodrugs according to any one of claims 1 to 11, and also at least one pharmaceutically acceptable excipient.

20. Use of a compound of formula (I) or one of its prodrugs according to any one of claims 1 to 11 for preparing a medicament intended for the treatment of glaucoma.

21. Compound of formula (I) or one of its prodrugs according to any one of claims 1 to 11, as EP2 agonist.

22. A method of treatment of glaucoma, which comprises administering to a patient an effective dose of a compound of formula (I) or one of its prodrugs according to any one of claims 1 to 11.

23. Compound of formula (I) or one of its prodrugs according to any one of claims 1 to 11 as a medicament.

24. Combination of a compound of formula (I) or one of its prodrugs with beta-blockers, prostaglandins, sympathomimetic collyres, inhibitors of carbonic anhydrase, or parasympathomimetic collyres.

5

13. Compound of formula:

III(b): 5-(3-Fluorophenyl)-2-methyl-benzoic acid;

III(d): 2-Fluoro-3-(3-fluorophenyl)-5-methoxy-benzoic acid;

III(e): 2-Fluoro-3-(3-fluorophenyl)-5-methyl-benzoic acid;

III(f): 2-Fluoro-5-(3-fluorophenyl)-3-methyl-benzoic acid;

III(g): 2-Chloro-5-(3-fluorophenyl)benzoic acid;

III(i): 3-(3-Fluorophenyl)-5-methoxy-benzoic acid;

III(j): 2,6-difluoro-3-(3-fluorophenyl)benzoic acid;

III(k): 5-(3-Fluorophenyl)-2-methoxy-3-methyl-benzoic acid;

III(m): 5-(3-Fluorophenyl)-2,3-dimethyl-benzoic acid;

III(n): 3-Cyano-5-(3-fluorophenyl)benzoic acid;

III(o): 6-Fluoro-3-(3-fluorophenyl)-2-methyl-benzoic acid;

III(p): 3-Fluoro-5-(3-fluorophenyl)-2-methyl-benzoic acid;

III(q): 3-(3-Fluorophenyl)-5-methyl-benzoic acid;

III(s): 5-(3,4-Difluorophenyl)-2,3-dimethyl-benzoic acid;

III(t): 5-(3,5-Difluorophenyl)-2,3-dimethyl-benzoic acid;

III(u): 2,3-Dimethyl-5-phenyl-benzoic acid;

IV(a): Ethyl 2-(3-amino-2,4-difluorophenoxy)acetate;

IV(b): Isopropyl 2-(3-amino-2,4-difluoro-phenoxy)acetate;

2-Chloro-6-fluoro-3-methoxy-aniline;

2-Amino-3-fluoro-6-methoxy-benzonitrile;

X(a): 3-Amino-2,4-difluoro-phenol;

X(b): 3-Amino-2-fluoro-4-methyl-phenol;

X(d): 3-Amino-4-chloro-2-fluoro-phenol;

X(e): 3-Amino-4-fluoro-2-methyl-phenol;

X(f): 3-Amino-2-chloro-4-fluoro-phenol;

X(g): 3-Amino-2,4-difluoro-5-methyl-phenol;

X(h): 3-amino-4-fluoro-2,5-dimethyl-phenol;

or one of its enantiomers.

14. Process for the manufacture of a compound of formula (II), wherein said process comprises the following step:



IX II

in which R1a, R1b, R1c, R2, R3, R4, R5, R7, R8 and R6 are as defined in any one of claims 1 to 11.

15. Process for the manufacture of a compound of formula (II), wherein said process comprises the following step:



I II

in which R1a, R1b, R1c, R2, R3, R4, R5, R7, R8 and R6 are as defined in any one of claims 1 to 11.

16. Medicament, wherein it comprises a compound of formula (I) or one of its prodrugs according to any one of claims 1 to 11.

17. Medicament according to claim 16 wherein the prodrug is a compound of formula (II) as defined in claims 7 to 11.

18. Pharmaceutical composition, wherein it comprises a compound of formula (I) or one of its prodrugs according to any one of claims 1 to 11, and also at least one pharmaceutically acceptable excipient.

19. Use of a compound of formula (I) or one of its prodrugs according to any one of claims 1 to 11 in the manufacture of a medicament for the treatment of glaucoma.

20. Compound of formula (I) or one of its prodrugs according to any one of claims 1 to 11, as EP2 agonist.

21. Compound of formula (I) or one of its prodrugs according to any one of claims 1 to 11 as a medicament.

22. Combination of a compound of formula (I) or one of its prodrugs with beta-blockers, prostaglandins, sympathomimetic collyres, inhibitors of carbonic anhydrase, or parasympathomimetic collyres.